MarginsXMarginsX
Home › Markets › Health Care › TECX

Tectonic Therapeutic Inc. (TECX)

TECX trades on Nasdaq in Health Care, Biotechnology: Biological Products (No Diagnostic Substances). Numbers below come from the Nasdaq screener and SEC filings, each with its source.

Price · November 16, 2026
$20.98
-0.76% on the day
Market cap
$418.5M
Small cap
Revenue
Not reported in SEC XBRL data
Net income
Not reported in SEC XBRL data

Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026.

Profile

FieldValue
TickerTECX on Nasdaq
SectorHealth Care
IndustryBiotechnology: Biological Products (No Diagnostic Substances)
CountryUnited States
IPO year2018
SEC CIK0001681087
SEC industry codeBiological Products, (No Diagnostic Substances)
Incorporated inNY

Financials

Not reported in SEC XBRL data.

Warning signs

Cash runway
40.7 months
$234.7M cash at September 30, 2026
Share count, 1 year
+6.6%
2025-11-03 to 2026-10-30 · +437.0% over 3 years
Going-concern doubt
No
10-Q filed November 5, 2026
Insider net buying, 12 months
-$456K
Through September 30, 2026
SignFindingSource
Going concernNo going-concern finding.
"In accordance with Accounting Standards Update ( ASU ) 2014-15, Disclosure of Uncertainties about an Entity's Ability to Continue as a Going Concern (Subtopic 205-40), the Company has evaluated whether there are conditions and events, considered in the aggregate, that raise substantial doubt about the Company's ability to continue as a going concern within one year after the date that these condensed consolidated fin"
10-Q 2026-11-05
Cash and burn$234.7M cash; operating cash flow -$17.3M a quarter.Report 2026-09-30
Shares outstanding19,948,037 (2026-10-30); 18,716,280 a year earlier; 44,573,911 three years earlier. 3y figure adjusted for split (1-for-12 overall).Cover page 2026-10-30
Reverse splits, 3 years1; latest 1-for-12 on 2024-06-21Source 2024-06-21
Shelf and offerings, 12 months0 S-3/F-3 shelf filings; 0 424B5 takedownsNone on EDGAR
Exchange deficiency notices, 12 monthsNoneNone on EDGAR
AuditorDeloitte & Touche LLP, Boston, Massachusetts, United StatesPCAOB Form AP 2026-03-17
Late filings, 12 monthsNoneNone on EDGAR
Insider trades, 12 monthsBought $182K, sold $639K on the open marketSEC Forms 3/4/5 data sets 2026-09-30

From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.

Quarterly results

QuarterRevenueNet incomeOp. cash flowCashTotal debtTTM revenueSource
Q3 2026
2026-09-30
Not filed-$21.3M-$14.9M$234.7MNo debt tagsNeeds four quarters10-Q 2026-11-05
Q2 2026
2026-06-30
Not filed-$22.3M-$21.5M$227.1MNo debt tagsNeeds four quarters10-Q 2026-11-05
Q1 2026
2026-03-31
Not filed-$25.2M-$18.4M$236.9MNo debt tagsNeeds four quarters10-Q 2026-11-05
Q4 2025
2025-12-31
Not filed-$19.2M-$14.5M$253.8MNo debt tagsNeeds four quarters10-K 2026-02-26
Q3 2025
2025-09-30
Not filed-$19.0M-$17.8M$268.4MNo debt tagsNeeds four quarters10-Q 2026-11-05
Q2 2025
2025-06-30
Not filed-$20.0M-$14.7M$287.4MNo debt tagsNeeds four quarters10-Q 2026-11-05
Q1 2025
2025-03-31
Not filed-$15.9M-$13.1M$306.2MNo debt tagsNeeds four quarters10-Q 2026-11-05
Q4 2024
2024-12-31
Not filed-$12.4M-$16.8M$141.2MNo debt tagsNeeds four quarters10-K 2026-02-26

From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).

Key SEC documents

DocumentFormFiled
Latest prospectus or offering document424B32025-07-15
Latest annual report10-K2026-02-26
Latest quarterly / interim10-Q2026-11-05
Latest current report8-K2026-11-05
Latest proxyDEFA14A2026-04-24

Source: SEC EDGAR submissions feed, 582 recent filings. All filings on EDGAR.

Price moves

WindowReturn
1 week+2.4%
1 month-0.8%
3 months-37.8%
Year to date+1.3%
1 year+20.3%
From 52-week high-44.3%

Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.

Peers in Biotechnology: Biological Products (No Diagnostic Substances)

TickerCompanyPriceDayMarket cap
TVGNTevogen Inc.$6.22+3.67%$422.2M
IRLAIRulya Therapeutics Inc.$37.36-6.13%$405.0M
SLBTSL Science Holding Limited$0.7195-3.42%$403.5M
FENCFennec Pharmaceuticals Inc.$12.76+9.81%$450.5M
CADLCandel Therapeutics Inc.$5.81-6.29%$455.8M
ALECAlector Inc.$2.57+1.18%$382.6M
RGNXREGENXBIO Inc.$7.32-4.19%$484.0M
CCCCC4 Therapeutics Inc.$2.65-3.99%$348.0M

The full dossier has every filing, three years of financials, private raises and the people who signed them.

Open the full dossier